Initiates clinical discovery with Lysando’s Artilysin® technology to address bacterial infections in dairy cow’s
South Korea (Jinju) headquartered CDMO and biotechnology company, Amicogen, have partnered with Lysando to address the rising issue of mastitis in dairy cows caused by multi-resistant bacteria.
Amicogen specializes in industrial enzyme production and drug development, while Lysando will work to leverage its expertise in the development of the antimicrobial Artilysin®.
Mastitis – a bacterial infection of the udder caused by various, often multi-resistant bacteria strains – is rapidly spreading, particularly in Asia. This leads to animal suffering and significant milk production loss, causing the global dairy industry about $20-30 billion in annual revenue loss. According to recent research, antibiotic overuse in animal husbandry has driven a rapid increase in multidrug-resistant pathogens. Approximately 70% of all antibiotics produced globally are used in agriculture, often as preventative measures, which accelerates resistance spread.
Amicogen and Lysando are partnering to develop an innovative solution for this pressing issue. Utilizing their combined expertise, the companies are developing a treatment that is both effective and sustainable, reducing the economic impact of mastitis on farmers.
“Our Artilysin® technology has shown significant promise in addressing bacterial infections and we believe that this partnership will make a real difference in the fight against mastitis”, added Dr. Kerstin Emmrich, Director R&D, Lysando AG.
The joint effort between Amicogen and Lysando represents a significant step towards combating antibiotic resistance and improving animal health. The companies envisage continuing their research to deliver innovative solutions to critical challenges.
